OncView™ features trusted experts who actively address the latest data, practice advice, products, and devices in cancer care. Expert, multidisciplinary oncology providers can engage with these educational offerings to learn about the science driving treatment options.
October 7th 2022
Joyce O’Shaughnessy, MD discusses a modern approach to treating patients with early-stage HER2+ breast cancer, elaborating on the entire process from the initial determination of patient eligibility to monitoring in the curative setting.
May 19th 2022
Dr Rafael Fonseca presents an overview of recent updates in the treatment of multiple myeloma and discusses strategies for incorporating the evidence into clinical practice.
May 6th 2022
Sarah M. Tolaney, MD, MPH, discusses the range of treatment options for early-stage HER2+ breast cancer, including subcutaneous options and investigational therapies.
March 30th 2022
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.
March 22nd 2022
This OncView program features content experts who share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.
March 4th 2022
An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.
February 15th 2022
Virginia Kaklamani, MD, DSc, provides a discussion on the frontline and maintenance therapies available for the management of early-stage HER2+ breast cancer.
November 18th 2021
A leading expert in lung cancer provides insights on recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.
November 16th 2021
Dr Aaron Berger discusses recent advances in treatment and management of patients with nonmetastatic castrate-resistant prostate cancer.